Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 13;5(11):1072-1082.
doi: 10.1016/j.molmet.2016.08.004. eCollection 2016 Nov.

Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice

Sebastian Brachs  1 , Angelika F Winkel  2 , Hui Tang  3 , Andreas L Birkenfeld  4 , Bodo Brunner  5 , Kerstin Jahn-Hofmann  6 , Daniel Margerie  7 , Hartmut Ruetten  8 , Dieter Schmoll  9 , Joachim Spranger  10
Affiliations

Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice

Sebastian Brachs et al. Mol Metab. .

Abstract

Objective: Non-alcoholic fatty liver disease is a world-wide health concern and risk factor for cardio-metabolic diseases. Citrate uptake modifies intracellular hepatic energy metabolism and is controlled by the conserved sodium-dicarboxylate cotransporter solute carrier family 13 member 5 (SLC13A5, mammalian homolog of INDY: mINDY). In Drosophila melanogaster and Caenorhabditis elegans INDY reduction decreased whole-body lipid accumulation. Genetic deletion of Slc13a5 in mice protected from diet-induced adiposity and insulin resistance. We hypothesized that inducible hepatic mINDY inhibition should prevent the development of fatty liver and hepatic insulin resistance.

Methods: Adult C57BL/6J mice were fed a Western diet (60% kcal from fat, 21% kcal from carbohydrate) ad libitum. Knockdown of mINDY was induced by weekly injection of a chemically modified, liver-selective siRNA for 8 weeks. Mice were metabolically characterized and the effect of mINDY suppression on glucose tolerance as well as insulin sensitivity was assessed with an ipGTT and a hyperinsulinemic-euglycemic clamp. Hepatic lipid accumulation was determined by biochemical measurements and histochemistry.

Results: Within the 8 week intervention, hepatic mINDY expression was suppressed by a liver-selective siRNA by over 60%. mINDY knockdown improved hepatic insulin sensitivity (i.e. insulin-induced suppression of endogenous glucose production) of C57BL/6J mice in the hyperinsulinemic-euglycemic clamp. Moreover, the siRNA-mediated mINDY inhibition prevented neutral lipid storage and triglyceride accumulation in the liver, while we found no effect on body weight.

Conclusions: We show that inducible mINDY inhibition improved hepatic insulin sensitivity and prevented diet-induced non-alcoholic fatty liver disease in adult C57BL6/J mice. These effects did not depend on changes of body weight or body composition.

Keywords: 2-DG, 2-Deoxy-d-glucose; Citrate transport; EE, energy expenditure; EGP, endogenous glucose production; FA, fatty acids; FLD, fatty liver disease; GIR, glucose infusion rate; HE clamp, hyperinsulinemic-euglycemic clamp; HFD, high-fat diet; IEX, anion-exchange high-performance liquid chromatography; INDY, ‘I'm not dead Yet’; INDY/Slc13a5; Insulin resistance; KO, knockout; Lipid accumulation; ORO, oil red O; RER, respiratory exchange ratio; SCR, non-silencing scrambled control siRNA; SKM, skeletal muscle; Steatosis; T2D, type-2 diabetes; TCA, tricarboxylic acid; WAT, white adipose tissue; WD, western diet; e, epididymal; mINDY, Slc13a5/SLC13A5; p, perirenal; s, subcutaneous; siINDY, mINDY-specific siRNA; siRNA; solute carrier family 13, member 5.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
In vitro (A–C) and in vivo (D and E) validation of mINDY-specific siRNA (siINDY). (A) Dose–response curves upon transfection of HEK293 cells stably overexpressing mINDY carrying a FLAG-tag (HEK293-mINDY) with siINDY and its unmodified form (siINDY*) (n = 2). (B) Transfection of HEK293-mINDY with siINDY reduced mINDY protein in a concentration-dependent manner, determined by anti-FLAG In-Cell Western Assay (n = 3). The black arrow indicates background fluorescence signal of HEK293 wild-type cells analyzed in parallel. (C) Transfection of HEK293-mINDY cells with siINDY reduced cellular citrate uptake (n = 3). (D) Pilot mouse study to evaluate the siRNA efficacy. mINDY mRNA expression in liver 2 and 6 days after injection normalized to GAPDH and control siRNA at day 2 (n = 3). (E) mINDY mRNA expression in liver, kidney, and muscle tissue after 8 weeks of siRNA treatment normalized to GAPDH and control siRNA in liver (n = 4). Data are represented as mean ± SEM. Two-way ANOVA with Bonferroni's multiple comparisons test. Scrambled control siRNA (SCR): open bars; off-target-specific mINDY-unrelated siRNA (OT): fasciated bars; mINDY-specific unmodified siRNA (siINDY*): grey triangle; mINDY-specific modified siRNA (siINDY): black bars.
Figure 2
Figure 2
Liver-selective mINDY-specific siRNA approach. (A) Schematic of the mouse experiment. (B) mRNA expression of indicated genes in liver of clamped mice normalized to GAPDH (n = 7, two-tailed Student's t-test with Welch's correction). (C–E) Body composition measurement for fat mass (C), free fluids (D), and lean mass (E) at start (0 wk), after 5 weeks (5 wk) and before catheterization (7 wk) (n = 16). (F) Weight gain during intervention (n = 16). Data represent mean ± SEM. Black arrows: Recording of body weight/siRNA injection, Grey arrows: Procedures: BC: Body composition, MCA: Metabolic cage analysis, OP: Catheterization.
Figure 3
Figure 3
Metabolic characterization of siRNA-treated mice during metabolic cage analysis (A–D, n = 10) and ipGTT (E–F). (A) Food intake (left) and liquid consumption (with 6% sucrose, right) during light- and dark-phase (repeated measurement ANOVA with Bonferroni's multiple comparisons test). (B) Locomotor activity. (C) Energy expenditure. (D) Respiratory exchange ratio (VCO2/VO2). (E) Plasma glucose during ipGTT (n = 16). (H) According insulin levels during ipGTT (n = 15). Data represent mean ± SEM. Grey background indicates dark-phase.
Figure 4
Figure 4
Improvement of insulin sensitivity with mINDY-specific siRNA during HE clamp. (A) Blood glucose (top) at basal and insulin-stimulated phase and according glucose infusion rate (GIR, bottom) to maintain plasma glucose at 120 mg/dl. (B) Insulin-mediated reduction of plasma NEFA. (C) Endogenous glucose production (EGP). (D). Suppression of EGP. (E) Whole-body glucose uptake during steady state. (F) 2-DG uptake of SKM (Gastrocnemius) and epididymal WAT. Data represent mean ± SEM. n = 7. Two-tailed Student's t-test with Welch's correction.
Figure 5
Figure 5
mINDY-specific siRNA decreased hepatic lipid content. (A) Weight of indicated organs and epididymal (e), perirenal (p), and subcutaneous (s) WAT after 16 h fasting. (B) Representative H&E staining of liver. (C) Representative ORO staining. (D) Quantification of ORO stainings by densitometric analysis. (E) Triglyceride content in liver lysates. Data represent mean ± SEM. n = 4. One-tailed Student's t-test with Welch's correction. Black scales indicate 50 μm.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–1395. - PubMed
    1. Haslam D.W., James W.P. Obesity. Lancet. 2005;366(9492):1197–1209. - PubMed
    1. Aguilar-Valles A., Inoue W., Rummel C., Luheshi G.N. Obesity, adipokines and neuroinflammation. Neuropharmacology. 2015;96(Pt A):124–134. - PubMed
    1. Vandevijvere S., Chow C.C., Hall K.D., Umali E., Swinburn B.A. Increased food energy supply as a major driver of the obesity epidemic: a global analysis. Bulletin of the World Health Organization. 2015;93(7):446–456. - PMC - PubMed
    1. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99–S112. - PubMed

Publication types